A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China
Autor: | Mu Zeng, Muzheng Li, Nenghua Qi, Yanxia Liu, Fang Li, Jianjun Tang, Zhijian Wu, Mingxian Chen, Wei Li, Tudahun Ilyas, Qiming Liu, Qing-yi Zhu, Yaqin Chen |
---|---|
Rok vydání: | 2021 |
Předmět: |
Male
China Pediatrics medicine.medical_specialty Time Factors medicine.medical_treatment Developing country Heart failure Comorbidity Cardiac amyloidosis Risk Assessment Predictive Value of Tests Risk Factors medicine Humans Diseases of the circulatory (Cardiovascular) system Immunoglobulin Light-chain Amyloidosis Aged Retrospective Studies Angiology Light chain Chemotherapy Missed Diagnosis business.industry Research Real-world study Middle Aged Prognosis medicine.disease Cardiac surgery Early Diagnosis Southern china RC666-701 Female Cardiomyopathies Cardiology and Cardiovascular Medicine business Developed country |
Zdroj: | BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-10 (2021) BMC Cardiovascular Disorders |
ISSN: | 1471-2261 |
DOI: | 10.1186/s12872-021-02256-3 |
Popis: | Background Light-chain cardiac amyloidosis (AL-CA) has been highly valued in developed countries, but in developing countries, the recognition and diagnosis of this condition is still limited. There are currently few reports on a large number of Chinese patients with AL-CA. The present study aimed to report real-world clinical characteristics and prognosis of AL-CA in China. Methods and results Consecutive patients with AL-CA diagnosed at the Second Xiangya Hospital of Central South University between June 2012 and September 2020 were reviewed. A total of 170 patients with AL-CA have been recruited, whose mean ages were 60.81 ± 10.46. 70.59% of the patients were male. They were from eight provinces in southern China, 55.7% were referred patients, and 37.3% had been misdiagnosed previously. 64 (37.6%) patients received chemotherapy. The median survival time for patients with AL-CA was 8.00 months, and survival time for patients who received chemotherapy was 13.00 months, which was significantly longer than that of patients with palliative treatment (13.00 vs 6.00, p = 0.004). Conclusions Although clinicians have improved their understanding of AL-CA in recent years, the prognosis of AL-CA is still poor, and the misdiagnosis rate and missed diagnosis rate are still very high in China. It is imperative to improve the recognition and early diagnosis of this condition, which may require multidisciplinary collaboration among cardiologists, hematologists and nephrologists. |
Databáze: | OpenAIRE |
Externí odkaz: |